Definitive Healthcare Corp. (NASDAQ:DH) Given Consensus Rating of “Hold” by Analysts

Shares of Definitive Healthcare Corp. (NASDAQ:DH) have earned a consensus rating of “Hold” from the twelve ratings firms that are covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $5.35.

Several equities research analysts have recently commented on the company. The Goldman Sachs Group reduced their price objective on Definitive Healthcare from $4.50 to $3.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Stephens assumed coverage on Definitive Healthcare in a research report on Friday, December 20th. They issued an “equal weight” rating and a $5.00 price target for the company. Barclays lowered their price objective on Definitive Healthcare from $4.00 to $3.00 and set an “underweight” rating on the stock in a research report on Monday, March 3rd. Finally, Needham & Company LLC restated a “hold” rating on shares of Definitive Healthcare in a research note on Thursday, January 16th.

Definitive Healthcare Stock Up 4.4 %

Definitive Healthcare stock opened at $2.59 on Tuesday. The firm has a market cap of $292.44 million, a price-to-earnings ratio of -0.84, a PEG ratio of 4.06 and a beta of 1.48. The company has a current ratio of 2.49, a quick ratio of 2.49 and a debt-to-equity ratio of 0.33. Definitive Healthcare has a 12 month low of $2.15 and a 12 month high of $7.66. The stock has a fifty day simple moving average of $3.57 and a two-hundred day simple moving average of $4.10.

Definitive Healthcare (NASDAQ:DH) last issued its quarterly earnings data on Thursday, February 27th. The company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.04). Definitive Healthcare had a negative net margin of 142.38% and a positive return on equity of 1.76%. The company had revenue of $62.29 million for the quarter, compared to the consensus estimate of $60.60 million. Equities analysts predict that Definitive Healthcare will post 0.16 EPS for the current fiscal year.

Institutional Trading of Definitive Healthcare

A number of institutional investors have recently bought and sold shares of DH. Price T Rowe Associates Inc. MD lifted its stake in Definitive Healthcare by 20.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 20,572 shares of the company’s stock worth $85,000 after purchasing an additional 3,496 shares during the last quarter. Principal Financial Group Inc. raised its holdings in shares of Definitive Healthcare by 9.7% in the fourth quarter. Principal Financial Group Inc. now owns 43,960 shares of the company’s stock worth $181,000 after buying an additional 3,874 shares during the period. Rhumbline Advisers lifted its stake in shares of Definitive Healthcare by 5.2% during the 4th quarter. Rhumbline Advisers now owns 81,316 shares of the company’s stock worth $334,000 after acquiring an additional 4,034 shares during the last quarter. Canada Pension Plan Investment Board boosted its holdings in Definitive Healthcare by 18.1% during the 4th quarter. Canada Pension Plan Investment Board now owns 29,300 shares of the company’s stock valued at $120,000 after acquiring an additional 4,500 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Definitive Healthcare by 6.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 81,358 shares of the company’s stock valued at $334,000 after acquiring an additional 4,748 shares during the last quarter. 98.67% of the stock is currently owned by institutional investors.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.